Moderna Settles Patent Dispute, Boosting Market Confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2024
0mins
Should l Buy MRNA?
Source: TipRanks
Moderna's stock surged by nearly 10% as it crossed above the 5-day SMA, reflecting strong investor sentiment following a significant patent settlement.
The company has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, which alleviates a major legal burden and is expected to enhance market confidence. Analysts view this settlement as a positive development, noting that it is better than feared, and it allows Moderna to focus on future growth, with expectations of reaching $4.5 billion to $5 billion in cash by the end of 2026.
This resolution not only reduces potential litigation costs but also positions Moderna favorably for future vaccine developments, reinforcing its competitive edge in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 54.980
Low
17.00
Averages
32.47
High
63.00
Current: 54.980
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations
- Recommendation Revision: The HHS vaccines advisory committee has decided to walk back its previous threat to stop recommending mRNA vaccines, leading to a rise in stock prices for companies like Moderna and BioNTech during Wednesday's trading, indicating a restoration of market confidence in these vaccines.
- Positive Market Reaction: With the committee's adjustment, mRNA vaccines, widely used during the pandemic, are back in focus for investors, enhancing expectations for future vaccine demand for companies like Moderna (MRNA) and BioNTech (BNTX).
- Safety Controversies: Despite the positive signals from the committee's decision, some ACIP members have raised concerns about the potential harm of DNA elements in the vaccines, which could affect public acceptance and potentially impact future sales for these companies.
- Financial Outlook: BioNTech has outlined a revenue target of €2 billion to €2.3 billion for 2026, and despite facing leadership transitions and competitive pressures, the company continues to advance its late-stage oncology pipeline, demonstrating confidence in future growth.
See More
BioNTech's Strategic Shift and Clinical Progress
- Executive Transition: Co-founders Ugur Sahin and Özlem Türeci plan to lead a new venture by the end of 2026, prompting BioNTech's Supervisory Board to initiate a search for successors, which may impact the company's strategic direction and market confidence.
- Clinical Trial Progress: BioNTech expects to have 15 ongoing Phase 3 clinical trials by the end of 2026, covering major cancer types, with the resulting data informing regulatory and launch plans, potentially enhancing the company's competitiveness in oncology.
- Stock Performance: BioNTech's shares have decreased by 3.03% over the past 12 months, currently trading at $87.60, which is 18% below its 100-day simple moving average, reflecting a bearish market sentiment that could affect investor confidence.
- Market Momentum Analysis: With a Benzinga Edge score of 19.82 indicating weak momentum, BioNTech's stock is underperforming the broader market, although the strategic pivot may present future growth opportunities, current market sentiment remains negative.
See More
BioNTech Announces Earnings, But That's Not the Reason for the 17% Drop in Stock Price.
- Quarterly Loss: BioNTech reported a significant quarterly loss, indicating challenges in its operations.
- Leadership Changes: The company announced the departure of its co-founders, marking a significant shift in its leadership structure.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
Surge in Oil Prices Triggers Market Turmoil
- Oil Price Surge: U.S. crude futures have surged above $100 per barrel for the first time since mid-2022, driven by Iran's threats to close the Strait of Hormuz, with a staggering 35.6% increase last week marking the largest weekly gain in futures history, which has directly impacted the stock market, leading to the Dow's worst week in nearly a year.
- Economic Pressure Intensifies: The rising oil prices have prompted Democrats to frame the conflict as a catalyst for increased living costs, potentially affecting the upcoming midterm elections negatively, while Republicans hope for a swift resolution to avoid economic fallout, highlighting the intersection of politics and economics.
- FDA Leadership Change: Vinay Prasad, the FDA's vaccine chief, announced his resignation effective at the end of April following widespread criticism of his decisions from the biotech and pharmaceutical sectors, illustrating the challenges and pressures regulatory bodies face in managing public health crises.
- Changing Canadian Consumption Trends: Canadians continue to boycott U.S. goods, with data indicating a shift towards domestic brands and increased local tourism spending, a trend that could significantly impact Canada's GDP and inflation rates in the long term.
See More
uniQure Shares Surge Following FDA Official's Departure
- Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
- Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
- Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
- Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
See More
mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations
- Recommendation Revision: The HHS vaccines advisory committee has decided to walk back its previous threat to stop recommending mRNA vaccines, leading to a rise in stock prices for companies like Moderna and BioNTech during Wednesday's trading, indicating a restoration of market confidence in these vaccines.
- Positive Market Reaction: With the committee's adjustment, mRNA vaccines, widely used during the pandemic, are back in focus for investors, enhancing expectations for future vaccine demand for companies like Moderna (MRNA) and BioNTech (BNTX).
- Safety Controversies: Despite the positive signals from the committee's decision, some ACIP members have raised concerns about the potential harm of DNA elements in the vaccines, which could affect public acceptance and potentially impact future sales for these companies.
- Financial Outlook: BioNTech has outlined a revenue target of €2 billion to €2.3 billion for 2026, and despite facing leadership transitions and competitive pressures, the company continues to advance its late-stage oncology pipeline, demonstrating confidence in future growth.
See More
BioNTech's Strategic Shift and Clinical Progress
- Executive Transition: Co-founders Ugur Sahin and Özlem Türeci plan to lead a new venture by the end of 2026, prompting BioNTech's Supervisory Board to initiate a search for successors, which may impact the company's strategic direction and market confidence.
- Clinical Trial Progress: BioNTech expects to have 15 ongoing Phase 3 clinical trials by the end of 2026, covering major cancer types, with the resulting data informing regulatory and launch plans, potentially enhancing the company's competitiveness in oncology.
- Stock Performance: BioNTech's shares have decreased by 3.03% over the past 12 months, currently trading at $87.60, which is 18% below its 100-day simple moving average, reflecting a bearish market sentiment that could affect investor confidence.
- Market Momentum Analysis: With a Benzinga Edge score of 19.82 indicating weak momentum, BioNTech's stock is underperforming the broader market, although the strategic pivot may present future growth opportunities, current market sentiment remains negative.
See More
BioNTech Announces Earnings, But That's Not the Reason for the 17% Drop in Stock Price.
- Quarterly Loss: BioNTech reported a significant quarterly loss, indicating challenges in its operations.
- Leadership Changes: The company announced the departure of its co-founders, marking a significant shift in its leadership structure.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
Surge in Oil Prices Triggers Market Turmoil
- Oil Price Surge: U.S. crude futures have surged above $100 per barrel for the first time since mid-2022, driven by Iran's threats to close the Strait of Hormuz, with a staggering 35.6% increase last week marking the largest weekly gain in futures history, which has directly impacted the stock market, leading to the Dow's worst week in nearly a year.
- Economic Pressure Intensifies: The rising oil prices have prompted Democrats to frame the conflict as a catalyst for increased living costs, potentially affecting the upcoming midterm elections negatively, while Republicans hope for a swift resolution to avoid economic fallout, highlighting the intersection of politics and economics.
- FDA Leadership Change: Vinay Prasad, the FDA's vaccine chief, announced his resignation effective at the end of April following widespread criticism of his decisions from the biotech and pharmaceutical sectors, illustrating the challenges and pressures regulatory bodies face in managing public health crises.
- Changing Canadian Consumption Trends: Canadians continue to boycott U.S. goods, with data indicating a shift towards domestic brands and increased local tourism spending, a trend that could significantly impact Canada's GDP and inflation rates in the long term.
See More
uniQure Shares Surge Following FDA Official's Departure
- Significant Stock Surge: uniQure's shares surged 31.39% to $18.75 in premarket trading following the announcement of FDA's biologics division head Vinay Prasad's resignation, extending a 33.99% increase from Friday, indicating strong market optimism about the company's future prospects.
- Regulatory Decision Controversy: During Prasad's tenure, he faced criticism for the FDA's rejection of uniQure's Huntington's disease gene therapy application, as the agency recommended a prospective randomized controlled study, adding regulatory uncertainty that could impact uniQure's market outlook.
- Clinical Trial Challenges: The FDA previously indicated that uniQure could pursue accelerated approval without a placebo control due to difficulties in enrolling Huntington's disease patients, reflecting regulatory flexibility for rare diseases, yet this has sparked ongoing debates about clinical trial design.
- Strong Market Reaction: Following the news of Prasad's departure, uniQure's shares reportedly jumped as much as 70% in after-hours trading, reflecting investor expectations for a potential easing of tensions between the company and the FDA, which could pave the way for future product approvals.
See More
